Abbott Laboratories (NYSE:ABT) Stock Gets Price Target Trim from Royal Bank Of Canada

Abbott Laboratories (NYSE:ABT) had its price objective cut by Royal Bank Of Canada from $130.00 to $125.00 in a report issued on Thursday,Benzinga reports. They currently have an outperform rating on the healthcare product maker’s stock.

A number of other analysts also recently issued reports on the company. TD Cowen reduced their price objective on Abbott Laboratories from $135.00 to $118.00 and set a “buy” rating on the stock in a research note on Thursday. Wolfe Research upgraded Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price objective for the company in a research report on Thursday, August 13th. Weiss Ratings upgraded Abbott Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, September 18th. Wells Fargo & Company lifted their price target on shares of Abbott Laboratories from $112.00 to $119.00 and gave the stock an “overweight” rating in a research note on Thursday. Finally, UBS Group lowered their price target on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating on the stock in a report on Tuesday, July 28th. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $118.32.

Abbott Laboratories Price Performance

ABT opened at $103.70 on Thursday. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The company has a fifty day simple moving average of $105.15 and a 200 day simple moving average of $98.32. The stock has a market cap of $179.45 billion, a P/E ratio of 38.70, a P/E/G ratio of 1.92 and a beta of 0.59. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $132.02.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 EPS for the quarter, hitting analysts’ consensus estimates of $1.42. Abbott Laboratories had a return on equity of 17.97% and a net margin of 9.75%. The company had revenue of $13.01 billion for the quarter, compared to analysts’ expectations of $12.99 billion. During the same quarter last year, the business earned $1.30 earnings per share. Abbott Laboratories’s revenue was up 14.5% on a year-over-year basis. On average, research analysts expect that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $2.52 annualized dividend and a yield of 2.4%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 94.03%.

Institutional Trading of Abbott Laboratories

Hedge funds have recently modified their holdings of the stock. IVC Wealth Advisors LLC purchased a new position in shares of Abbott Laboratories during the 3rd quarter valued at $241,000. Holos Integrated Wealth LLC raised its holdings in Abbott Laboratories by 40.3% in the 3rd quarter. Holos Integrated Wealth LLC now owns 888 shares of the healthcare product maker’s stock worth $92,000 after acquiring an additional 255 shares during the last quarter. Kingswood Wealth Advisors LLC grew its holdings in shares of Abbott Laboratories by 7.3% in the third quarter. Kingswood Wealth Advisors LLC now owns 12,712 shares of the healthcare product maker’s stock worth $1,257,000 after acquiring an additional 863 shares during the period. Financial Management Professionals Inc. grew its stake in shares of Abbott Laboratories by 2.1% during the 3rd quarter. Financial Management Professionals Inc. now owns 5,878 shares of the healthcare product maker’s stock valued at $581,000 after acquiring an additional 119 shares during the period. Finally, Compass Ion Advisors LLC raised its position in shares of Abbott Laboratories by 7.0% during the 3rd quarter. Compass Ion Advisors LLC now owns 5,106 shares of the healthcare product maker’s stock valued at $505,000 after buying an additional 332 shares in the last quarter. Institutional investors own 75.18% of the company’s stock.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: New data presented at the European Society for Medical Oncology showed Abbott’s whole-genome sequencing Oncodetect® test delivered a 30% absolute improvement in sensitivity for detecting colorectal-cancer recurrence within two years of surgery. Patients with detectable molecular residual disease also faced a 10.6-fold higher recurrence risk, supporting the test’s clinical value and Abbott’s broader cancer-care strategy. Abbott Oncodetect ESMO data
• Positive Sentiment: Wells Fargo upgraded its stance to “overweight” and raised its price target to $119, while other analysts retained buy or outperform ratings. These targets imply substantial potential upside and suggest Wall Street views the recent pullback as excessive. Wells Fargo rating
• Neutral Sentiment: Abbott’s pacemaker and molecular-diagnostics markets are projected to grow, providing long-term demand opportunities. However, the reports also identify procedure costs, regulatory hurdles, cybersecurity risks and changing disease prevalence as industry constraints. Pacemaker market forecast
• Negative Sentiment: Investors remain concerned about Abbott’s lowered 2026 sales-growth outlook. Management cited diabetes-related pricing pressure and weakness in the electrophysiology portfolio, issues that overshadowed a third-quarter earnings and revenue performance that broadly met expectations. Abbott 2026 guidance
• Negative Sentiment: Abbott plans to spin off its approximately $8.5 billion Nutrition business by 2027. Although the transaction could sharpen the company’s focus and unlock value, investors face near-term uncertainty over separation costs, portfolio mix and the growth profile of the remaining business. Abbott Nutrition spin-off
• Negative Sentiment: A comparative study claimed Catheter Precision’s LockeT device outperformed Abbott’s Perclose vascular-closure system. The potential competitive risk appears limited without evidence of meaningful revenue impact, but it adds pressure to Abbott’s medical-device franchise. LockeT and Perclose study

About Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.

The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.